From: Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
Weaning Days
IV
Enteral
1–2
75% of last study dose
3–4
50% of last study dose
5–6
25% of last study dose
7
Discontinue